Oral Factor Xa Inhibitors Market Trends
In May 2023, the World Health Organization (WHO) set an ambitious target to reduce premature deaths from non-communicable diseases by 25% by 2025. To achieve this, a major focus must be on combating cardiovascular diseases, particularly through the use of direct oral anticoagulants (DOACs). Since January 2022, more than 460,000 people have started using anticoagulant medications, and over 24 million prescriptions have been issued. This has helped prevent an estimated 17,000 strokes and 4,000 deaths. Atrial fibrillation (AF), which affects approximately 1.5 million people in England alone, is responsible for one in five strokes.
In January 2022, the NHS revised its guidelines to recommend edoxaban as the preferred option for prescribers due to its cost-effectiveness compared to other approved DOACs. This decision saved the NHS more than £100 million in medical costs.
Increasing Stroke Cases Drive the Demand for Anticoagulants
Globally, over 100 million people have experienced a stroke. More than 60% of strokes occur in individuals under the age of 70, with 16% affecting those under 50. By 2030, the economic impact of stroke is expected to reach a staggering US$1 trillion, representing about 0.66% of global GDP. When the right anticoagulants are used, the risk of ischemic stroke can be reduced. Identifying the most effective combination of antiplatelet and anticoagulant medications for stroke prevention remains a key medical goal. Oral direct factor Xa inhibitors have been approved by the U.S. FDA for stroke prevention.
High Costs Remain a Barrier for the Oral Factor Xa Inhibitors Market
Despite their benefits, the high cost of factor Xa inhibitors poses a significant challenge. The price for a 28-day treatment with factor Xa inhibitors is approximately US$3,784.20 per patient. Including follow-up costs, the total expense for a 28-day treatment course can reach as much as US$77,125.60. The average annual cost per patient for factor Xa inhibitor therapy is US$4,370.93. In the U.S., this cost disparity is expected to increase, potentially totaling more than US$14.1 billion annually by 2040. Factor Xa inhibitor thromboprophylaxis can be up to 1,980.6% more expensive than an aspirin regimen, due to the high main treatment costs, variable management fees, and follow-up care.
Recent Developments
- In August 2024, the “maximum fair price” (MFP) for ELIQUIS® (apixaban), which was chosen during the first round of government price setting under the Inflation Reduction Act (IRA), was announced by the U.S. Department of Health and Human Services, according to Pfizer Inc. As of January 1, 2026, Medicare will cover $231.00 for a 30-day equivalent supply of ELIQUIS, the medication’s necessary MFP.
- In February 2024, in countries where the CE mark is recognized, Roche announced the introduction of three new coagulation tests for the oral Factor Xa inhibitors: rivaroxaban, edoxaban, and apixaban.
Top Companies in the Oral Factor Xa Inhibitors Market
- Hansoh Pharma
- Pfizer
- Kelun Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- BrightGene
- GlaxoSmithKline
- Accord Healthcare
- Qilu Pharmaceutical
- Dr. Reddy’s Laboratories
- Chia Tai Tianqing Pharmaceutical
- Lupin
- HEC Pharma
- Cspc Ouyi Pharmaceutical
- Nanjing King-Friend Biochemical Pharmaceutical
- Jiangsu Hengrui Pharmaceuticals
- Bristol Myers Squibb
- Eugia Pharma
- Apotex
- Viatris
- Janssen Pharmaceuticals
- Shanghai Huilun Pharmaceutical
- Bayer
- Daiichi Sankyo
- Zydus
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/oral-factor-xa-inhibitors-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5291
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Visit Dental Specifics: https://www.towardsdental.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare